Daratumumab and isatuximab show comparable efficacy in newly diagnosed multiple myeloma

Prof Heinz Ludwig speaks to ecancer about a systematic review and meta-analysis comparing daratumumab- and isatuximab-based therapies in patients with newly diagnosed multiple myeloma.

He reports that both CD38-targeting monoclonal antibodies demonstrated broadly comparable efficacy, including overall response rates, depth of response, measurable residual disease negativity and progression-free survival.

Prof Ludwig explains that after adjusting for differences in control arm performance, daratumumab was associated with a higher overall response rate, while isatuximab was associated with fewer grade 3 or higher infections.

He also highlights that these findings may help inform treatment selection, although substantial differences between studies and the absence of direct head-to-head trials mean that further comparative research is needed.